Benitec Biopharma (BNTC) Equity Average: 2019-2025
Historic Equity Average for Benitec Biopharma (BNTC) over the last 5 years, with Mar 2025 value amounting to $299.6 million.
- Benitec Biopharma's Equity Average rose 2121.55% to $299.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $299.6 million, marking a year-over-year increase of 2121.55%. This contributed to the annual value of $23.7 million for FY2024, which is 1438.59% up from last year.
- Per Benitec Biopharma's latest filing, its Equity Average stood at $299.6 million for Q1 2025, which was up 73.33% from $172.8 million recorded in Q4 2024.
- Benitec Biopharma's 5-year Equity Average high stood at $299.6 million for Q1 2025, and its period low was $2.5 million during Q2 2023.
- Its 3-year average for Equity Average is $67.8 million, with a median of $18.9 million in 2023.
- In the last 5 years, Benitec Biopharma's Equity Average tumbled by 66.38% in 2022 and then surged by 2,121.55% in 2025.
- Over the past 5 years, Benitec Biopharma's Equity Average (Quarterly) stood at $13.2 million in 2021, then declined by 10.28% to $11.8 million in 2022, then spiked by 60.03% to $18.9 million in 2023, then surged by 815.02% to $172.8 million in 2024, then skyrocketed by 2,121.55% to $299.6 million in 2025.
- Its Equity Average stands at $299.6 million for Q1 2025, versus $172.8 million for Q4 2024 and $55.7 million for Q3 2024.